Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Barclays Maintains Equal-Weight on Biogen, Lowers Price Target to $244

Barclays analyst Carter Gould maintains Biogen (NASDAQ:BIIB) with a Equal-Weight and lowers the price target from $280 to $244.

byBenzinga Newsdesk

January 20, 2022

1 minute read

Barclays analyst Carter Gould maintains Biogen (NASDAQ:BIIB) with a Equal-Weight and lowers the price target from $280 to $244.

Watching Yatra Online, Hearing Co. Is Seeing Speculation Of A Takeover

By Benzinga Newsdesk

Today, 7:57 AM

https://twitter.com/DavidSeaburg/status/1605286958473052161?t=50Hiji0JSpheXO7DIc0LoQ&s=01

YTRA

News
Tech

Amazon Web Services Explains The Cause Of Dec. 7 Outage, Taking Steps To Avoid Similar Event

By Michael Cohen

Today, 7:57 AM

Amazon.Com Inc (NASDAQ: AMZN)'s Amazon Web Services (AWS) is revealing the cause of an outage that took down parts of its own services, along with third-party websites and online platforms that utilize AWS on Dec. 7.

AMZN

Ulta Beauty To $511? Here Are 5 Other Price Target Changes For Monday

By Lisa Levin

Today, 7:57 AM

Barclays boosted the price target on Ulta Beauty, Inc. (NASDAQ: ULTA) from $491 to $511. Barclays analyst Adrienne Yih maintained an Overweight rating on the stock. Ulta Beauty shares fell 1% to $407.41 in pre-market trading.

OKTA